| Revenue growth | Q2 revenue +16.0% YoY, +6.5% QoQ |
|---|---|
| Margins | EBITDA margin 41.8%, up 880 bps YoY on efficiency |
| Demand visibility | Healthy demand across all key markets; CDMO advanced discussions |
| Management confidence | CEO confident of sustaining momentum via capacity, pipeline |
Growth
Non-GPL revenue +20.8% YoY; CDMO +79.9% YoY; Generic API +11.0% YoY. H1 FY27 revenue ₹13,224 Mn (+11.1%), PAT ₹3,569 Mn (+41.9%).
Outlook
No numeric growth guidance given. Capacity adds: Dahej ~160KL and Phase 1 Solapur ~340KL in Q3 FY27; Ankleshwar ~100KL and Phase 2 Solapur ~125KL in Q4 FY27; Phase 3 ~535KL by FY29.
Risks
GPL revenue grew only 1% YoY on inventory rationalisation. Capex cycle is diluting asset turns (FATR 2.1x). Labour Code impact flagged on exceptional items.
Investor Presentation filed with NSE, NSE: ALIVUS. Summary written with AI assistance from the document.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,395.00
- Market cap
- ₹17,127 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 28.4×Sector 46.1×
- Promoter holding
- 74.85%-0.02% QoQ
- FII holding
- 5.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Employee Stock Options
Alivus Life Sciences allotted 1,95,833 equity shares to an employee who exercised ESOP options under its 2021 scheme. Paid-up capital rises to Rs. 24.59 Crore.
Alivus Life Sciences Results Update
Alivus Life Sciences reported Q2FY27 revenue of Rs. 6,820 Mn (up 16.0% YoY) and PAT of Rs. 1,968 Mn in a press release. Investors see record EBITDA margins of 41.8% and capex progress at Solapur and Taloja.
Alivus Life Sciences Q2 FY27 Results: Net Profit ₹196.7 Cr, Up 51.3% YoY
Alivus Life Sciences Ltd reported revenue from operations of ₹682 Cr (+16.0% YoY) and net profit of ₹196.7 Cr (+51.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹196.7 Cr · +51.3% YoY
Alivus Life Sciences Board Meeting Date
Alivus Life Sciences Ltd has scheduled a Board Meeting on October 29, 2026, to consider and approve its unaudited financial results for the period ended September 30, 2026.
Alivus Life Sciences Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements.
Alivus Life Sciences Legal & Regulatory
Alivus Life Sciences Limited received a GST order for FY 2020-22 involving a tax demand and penalty of Rs. 0.51 Crore. The company is currently assessing an appeal.
- Value
- ₹0.51 Cr